Literature DB >> 35240292

Nanobodies as molecular imaging probes.

Sarah Barakat1, Melike Berksöz2, Pegah Zahedimaram3, Sofia Piepoli4, Batu Erman5.   

Abstract

Camelidae derived single-domain antibodies (sdAbs), commonly known as nanobodies (Nbs), are the smallest antibody fragments with full antigen-binding capacity. Owing to their desirable properties such as small size, high specificity, strong affinity, excellent stability, and modularity, nanobodies are on their way to overtake conventional antibodies in terms of popularity. To date, a broad range of nanobodies have been generated against different molecular targets with applications spanning basic research, diagnostics, and therapeutics. In the field of molecular imaging, nanobody-based probes have emerged as a powerful tool. Radioactive or fluorescently labeled nanobodies are now used to detect and track many targets in different biological systems using imaging techniques. In this review, we provide an overview of the use of nanobodies as molecular probes. Additionally, we discuss current techniques for the generation, conjugation, and intracellular delivery of nanobodies.
Copyright © 2022 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cancer; Cell permeable peptide; Nanobody; Phage display; VHH

Mesh:

Substances:

Year:  2022        PMID: 35240292     DOI: 10.1016/j.freeradbiomed.2022.02.031

Source DB:  PubMed          Journal:  Free Radic Biol Med        ISSN: 0891-5849            Impact factor:   7.376


  2 in total

Review 1.  Nanobodies; new molecular instruments with special specifications for targeting, diagnosis and treatment of triple-negative breast cancer.

Authors:  Hamid Bakherad; Fahimeh Ghasemi; Maryam Hosseindokht; Hamed Zare
Journal:  Cancer Cell Int       Date:  2022-08-06       Impact factor: 6.429

Review 2.  Recent review of COVID-19 management: diagnosis, treatment and vaccination.

Authors:  Vivek P Chavda; Suneetha Vuppu; Toshika Mishra; Sathvika Kamaraj; Aayushi B Patel; Nikita Sharma; Zhe-Sheng Chen
Journal:  Pharmacol Rep       Date:  2022-10-10       Impact factor: 3.919

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.